Dr Giuseppe Barone

Paediatric Oncologist
Dr Barone

Overview

Dr Giuseppe Barone is a Consultant Paediatric Oncologist with a special interest in neuroblastoma and new drug development. He has been the clinical lead for neuroblastoma at Great Ormond Street Hospital since July 2016. He had previously worked at the National Cancer Institute in Bethesda (US) in the Cancer treatment Evaluation Program and at the Royal Marsden Hospital/Institute of Cancer Research in London (UK)

Dr Barone obtained a Wellcome Trust funded PhD working at The Institute of Cancer Research/University of London. His research evaluated aspects of biology of neuroblastoma and experimented novel drugs active in this disease.

Credentials

  • Neuroblastoma
  • Hepatoblastoma
  • Wilms Tumour
  • LCH

Education:

  • Ph.D in Molecular biology and cancer therapeutics (2016). The Institute of Cancer Research, London (UK)
  • CCT in Paediatrics/Paediatric Oncology with honours (Diploma di specializzazione in Pediatria ad indirizzo Oncologia Pediatrica) 2009. Catholic University of Sacred Heart, A Gemelli Hospital, Rome (Italy)
  • Bachelor of Surgery and Medicine with honours (Diploma di Laurea specialistica in medicina e chirurgia) 2004. Catholic University of Sacred Heart, A Gemelli Hospital, Rome (Italy)

Memberships:

  • RCPCH (Royal College of Paediatrics and Child Health)
  • SIOPEN (SIOP- Europe - Neuroblastoma Group)
  • ITCC (Innovative Treatment for Children with Cancer Consortium)
  • Neuroblastoma biology 
  • Smallmolecules  
  • Immunotherapy 

News & Publications

Barone, G., Tweddle, D.A., Shohet, J.M., Chesler, L., Moreno, L., Pearson, A.D., Van Maerken, T., 2014.  MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance. Current Drug Targets. 15 (1) pp. 114-123.

Barone, G., Anderson, J., Pearson, A.D.K., Chesler, L., 2013. New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK. Clin Cancer Res. 19 (21) pp. 5814-5821.

Riccardi, R*., Barone, G*., 2009. Severe infections in immunodepressed children. Minerva Pediatrica. 61 (6) pp. 854-856. (* joint first Authors)

Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, Elliott M, Moreno L, Barone G, Pearson AD, James PW, Tweddle DA, McNally RJ. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma.Br J Cancer. 2016 Oct 25;115(9):1048-1057

Morgenstern DA, Hargrave D, Marshall LV, Gatz SA, Barone G, Crowe T, Pritchard-Jones K, Zacharoulis S, Lancaster DL, Vaidya SJ, Chisholm JC, Pearson AD, Moreno L. Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experience. J Pediatr Hematol Oncol 2014, 36 (3), 218-223.

Moreno, L., Barone, G., Park, J. R., & Pearson, A. D. (2013). About the benefits of immunotherapy for high-risk neuroblastoma. J Clin Oncol, 31(5), 649-650. doi:10.1200/JCO.2012.47.4080

Moreno, L., Caron, H., Geoerger, B., Eggert, A., Schleiermacher, G., Brock, P., . . . Pearson, A. D. (2017). Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opin Drug Discov, 12(8), 801-811. doi:10.1080/17460441.2017.1340269

Di Francesco, A. M., Meco, D., Torella, A. R., Barone, G., D'Incalci, M., Pisano, C., . . . Riccardi, R. (2007). The novel atypical retinoid ST1926 is active in ATRA resistant neuroblastoma cells acting by a different mechanism. Biochemical pharmacology, 73(5), 643-655. doi:10.1016/j.bcp.2006.10.033

Di Francesco, A. M., Riccardi, A., Barone, G., Rutella, S., Meco, D., Frapolli, R., . . . Riccardi, R. (2005). The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan. Biochemical pharmacology, 70(8), 1125-1136. doi:10.1016/j.bcp.2005.07.009

Di Francesco, A. M., Ubezio, P., Torella, A. R., Meco, D., Pierri, F., Barone, G., . . . Riccardi, R. (2012). Enhanced cell cycle perturbation and apoptosis mediate the synergistic effects of ST1926 and ATRA in neuroblastoma preclinical models. Invest New Drugs, 30(4), 1319-1330. doi:10.1007/s10637-011-9689-2

Moreno, L., Barone, G., Park, J. R., & Pearson, A. D. (2013). About the benefits of immunotherapy for high-risk neuroblastoma. J Clin Oncol, 31(5), 649-650. doi:10.1200/JCO.2012.47.4080

Moreno, L., Caron, H., Geoerger, B., Eggert, A., Schleiermacher, G., Brock, P., . . . Pearson, A. D. (2017). Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opin Drug Discov, 12(8), 801-811. doi:10.1080/17460441.2017.1340269

Morgenstern, D. A., Hargrave, D., Marshall, L. V., Gatz, S. A., Barone, G., Crowe, T., . . . Moreno, L. (2014). Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experience. J Pediatr Hematol Oncol, 36(3), 218-223. doi:10.1097/MPH.0000000000000003

Refer your child to Dr Giuseppe Barone

Use the form below to refer your child for treatment. A member of our team will be in touch within 2 working days.

Your Details
Relationship to Patient:
Preferred Language:
Patient Details
What is the purpose of your referral?
Doctor Details
Funding Details
Who is paying for your treatment?

Mandatory fields

Dr Giuseppe Barone Details

You can contact Dr Giuseppe Barone through Great Ormond Street Hospital below.

Share Dr Giuseppe Barone profile with someone:

Browse A-Z